Number of the records: 1  

Developmental Changes in Peripherin-eGFP Expression in Spiral Ganglion Neurons

  1. 1.
    SYSNO ASEP0548736
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleDevelopmental Changes in Peripherin-eGFP Expression in Spiral Ganglion Neurons
    Author(s) Elliott, K. L. (US)
    Kersigo, J. (US)
    Lee, J. H. (US)
    Jahan, I. (US)
    Pavlínková, Gabriela (BTO-N) RID, ORCID
    Fritzsch, B. (US)
    Yamoah, E. N. (US)
    Number of authors7
    Source TitleFrontiers in Cellular Neuroscience. - : Frontiers Media
    Roč. 15, JUN 15 2021 (2021)
    Number of pages12 s.
    Languageeng - English
    CountryUS - United States
    Keywordsperipherin ; Prph-eGFP ; type II spiral ganglion neurons
    Subject RIVFH - Neurology
    OECD categoryNeurosciences (including psychophysiology
    R&D ProjectsGA20-06927S GA ČR - Czech Science Foundation (CSF)
    Method of publishingOpen access
    Institutional supportBTO-N - RVO:86652036
    UT WOS000667688500001
    EID SCOPUS85109015187
    DOI10.3389/fncel.2021.678113
    AnnotationThe two types of spiral ganglion neurons (SGNs), types I and II, innervate inner hair cells and outer hair cells, respectively, within the mammalian cochlea and send another process back to cochlear nuclei in the hindbrain. Studying these two neuronal types has been made easier with the identification of unique molecular markers. One of these markers, peripherin, was shown using antibodies to be present in all SGNs initially but becomes specific to type II SGNs during maturation. We used mice with fluorescently labeled peripherin (Prph-eGFP) to examine peripherin expression in SGNs during development and in aged mice. Using these mice, we confirm the initial expression of Prph-eGFP in both types I and II neurons and eventual restriction to only type II perikarya shortly after birth. However, while Prph-eGFP is uniquely expressed within type II cell bodies by P8, both types I and II peripheral and central processes continue to express Prph-eGFP for some time before becoming downregulated. Only at P30 was there selective type II Prph-eGFP expression in central but not peripheral processes. By 9 months, only the type II cell bodies and more distal central processes retain Prph-eGFP expression. Our results show that Prph-eGFP is a reliable marker for type II SGN cell bodies beyond P8, however, it is not generally a suitable marker for type II processes, except for central processes beyond P30. How the changes in Prph-eGFP expression relate to subsequent protein expression remains to be explored.
    WorkplaceInstitute of Biotechnology
    ContactMonika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700
    Year of Publishing2022
    Electronic addresshttps://www.frontiersin.org/articles/10.3389/fncel.2021.678113/full
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.